1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Suzhou Basecare Medical Corp. Ltd. Class H

Suzhou Basecare Medical Corp. Ltd. Class H

HHKEX:2170
1.38
HKD
+0.03
(+1.85%)
508.76MMarket Cap
Apr 01Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.12
0.21
0.3
0.4
0.52
0.76
1.09
0.85
- -
Basic EPS, GAAP
-0.58
-1.99
-3.29
-0.54
-0.45
-0.7
-0.87
-0.82
- -
Free Cash Flow per Basic Share
-0.12
-0.15
-0.27
-0.88
-1.16
-1.36
-1.18
-0.93
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.53
-3.52
1.06
6.27
5.82
5.12
4.18
3.42
3.42
Tangible Book Value per Share
-1.53
-3.52
1.06
6.24
5.79
4.11
3.29
2.53
2.53
Basic Weighted Avg Shares
267
267
267
265
274
274
274
274
274
Sales/Revenue/Turnover
33
56
81
107
141
208
299
233
- -
Operating Margin (%)
-162.25
-18.43
-67.51
-125.65
-154.91
-117.03
-89.88
-90.76
- -
Depreciation Expense
8
8
7
6
8
20
36
48
- -
Net Income, GAAP
-155
-531
-877
-144
-123
-192
-237
-223
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-474.95
-954.18
-1,081.33
-134.28
-87.06
-92.17
-79.25
-95.79
- -
Working Capital
54
63
242
1,642
1,413
1,020
785
567
567
LT Debt
3
1
1
26
73
267
300
289
289
Total Equity
-412
-946
281
1,715
1,592
1,398
1,142
935
935
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-14.43
-7.42
-12.81
-18.65
-21.51
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
29
37
54
LT Borrowings
296
304
289
LT Finance Leases
3
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
274
274
274
Market Capitalization
704
706
457

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
979
865
757
Cash, Cash Equivalents & STI
685
544
443
Accounts Receivable, Net
165
164
174
Inventories
92
124
101
Total Current Liabilities
195
198
190
Payables & Accruals
- -
- -
- -
ST Debt
29
37
54
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
90.76%
-18.14%
Free Cash Flow
- -
48.39%
-21.39%
Net Income, GAAP
- -
-4.85%
-5.73%
Sales/Revenue/Turnover
- -
26.6%
-22.01%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
208
2024
- -
- -
299
2025
- -
- -
233

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.7
2024
- -
- -
-0.87
2025
- -
- -
-0.82

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bo Liang
Full Time Employees
407
Sector
Health technology
Industry
Medical specialties
Address
No. 77 Jingu Road Suzhou JS China 215000
IPO Date
Feb 8, 2021
Website
basecare.cn
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Suzhou Basecare Medical Corporation Limited (2170.HK) is a biotechnology company specializing in genomic testing and precision medicine solutions for oncology and rare diseases. The company develops and offers clinical genetic testing services, including next-generation sequencing (NGS) panels such as tumor genomic profiling, hereditary cancer screening, and non-invasive prenatal testing (NIPT); companion diagnostic services for targeted therapies; and bioinformatics platforms for data analysis and interpretation. Basecare provides these offerings through its proprietary BasecareMDx brand and operates primarily in China, with expanding presence in Asia-Pacific regions. Founded in 2012 and headquartered in Suzhou, China, the company serves hospitals, clinics, and pharmaceutical partners in the healthcare sector. In recent developments, Basecare announced a strategic partnership with a leading international pharmaceutical firm in 2024 to co-develop companion diagnostics for novel cancer therapies, alongside securing a Series D funding round exceeding RMB 500 million to fuel expansion into Southeast Asia and enhance its AI-driven genomic analytics platform.